Transcription Factor-MicroRNA-Target Gene Networks Associated with Ovarian Cancer Survival and Recurrence

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Delfino, Kristin R ^a   Rodriguez Zas, Sandra L ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; BIOLOGICAL MARKER; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; HISTONE DEACETYLASE 3; MICRORNA; MICRORNA 144; MICRORNA 16; MICRORNA 182; MICRORNA 19A; MICRORNA 22; MICRORNA 381; MICRORNA 485; MICRORNA 497; MICRORNA 509; MICRORNA 521; MICRORNA 573; MICRORNA 770; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 2; PROTEIN FOS; PROTEIN NR5A1; SMALL UNTRANSLATED RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CLOCK; TRANSCRIPTION FACTOR ESR2; TRANSCRIPTION FACTOR ETS2; TRANSCRIPTION FACTOR HOXA1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; SURVIVAL RATE;

COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENES, NEOPLASM; HUMANS; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RNA, NEOPLASM; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84874872636     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058608     Document Type: Article

References (78)

1. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, et al. (2009) A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 114(3): 457-464.
2. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, et al. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68(2): 425-433.
3. Shih I, Davidson B, (2009) Pathogenesis of ovarian cancer: Clues from selected overexpressed genes. Future Oncol 5(10): 1641-1657.
4. Zaret KS, Carroll JS, (2011) Pioneer transcription factors: Establishing competence for gene expression. Genes Dev 25(21): 2227-2241.
5. Cancer Genome Atlas Research Network, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216): 1061-1068.
6. von Gruenigen VE, Huang HQ, Gil KM, Gibbons HE, Monk BJ, et al. (2010) A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: A gynecologic oncology group study. J Pain Symptom Manage 39(5): 839-846.
7. Smith BJ, Ko Y, Southey BR, Rodriguez-Zas SL (2007) BEEHIVE- A suite of tools to manage, analyze and interpret honey bee microarray experiments. Cold Spring Harbor, NY. May 6-8.
8. Delfino KR, Serao NV, Southey BR, Rodriguez-Zas SL, (2011) Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics 8(4): 173-178.
9. Serao NV, Delfino KR, Southey BR, Beever JE, Rodriguez-Zas SL, (2011) Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics 4: 49.
10. Delfino KR, Southey BR, Sweedler JV, Rodriguez-Zas SL, (2010) Genome-wide census and expression profiling of chicken neuropeptide and prohormone convertase genes. Neuropeptides 44(1): 31-44.
11. Fox J (2002) Cox proportional-hazards regression for survival data: Web appendix to An R and S-PLUS companion to applied regression. Available: http://cran.r-project.org/doc/contrib/Fox-Companion/appendix-cox-regression.pdf. Accessed 25 January 2012.
12. Clark TG, Bradburn MJ, Love SB, Altman DG, (2003) Survival analysis part I: Basic concepts and first analyses. Br J Cancer 89(2): 232-238.
13. Schaubel DE, Wei G, (2007) Fitting semiparametric additive hazards models using standard statistical software. Biom J 49(5): 719-730.
14. Le Bechec A, Portales-Casamar E, Vetter G, Moes M, Zindy PJ, et al. (2011) MIR@NT@N: A framework integrating transcription factors, microRNAs and their targets to identify sub-network motifs in a meta-regulation network model. BMC Bioinformatics. 12: 67.
15. Gene ontology. Available: http://www.geneontology.org/. Accessed 2 February 2012.
16. KEGG. Available: http://www.genome.jp/kegg/. Accessed 2 February 2012.
17. Kanehisa M, Goto S, (2000) KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1): 27-30.
18. Sherman BT, Huang da W, Tan Q, Guo Y, Bour S, et al. (2007) DAVID knowledgebase: A gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics 8: 426.
19. Medina I, Carbonell J, Pulido L, Madeira SC, Goetz S, et al. (2010) Babelomics: An integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling. Nucleic Acids Res 38(Web Server issue): W210-3.
20. Dragon database of ovarian cancer genes. Available: http://apps.sanbi.ac.za/ddoc/. Accessed 30 December 2011.
21. Killcoyne S, Carter GW, Smith J, Boyle J, (2009) Cytoscape: A community-based framework for network modeling. Methods Mol Biol 563: 219-239.
22. American Cancer Society. Available: http://www.cancer.org/. Accessed 30 December 2011.
23. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP, et al. (2008) Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27(18): 2575-2582.
24. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, et al. (2009) Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 4(4): e5311.
25. Dahiya N, Morin PJ, (2010) MicroRNAs in ovarian carcinomas. Endocr Relat Cancer 17(1): F77-F89.
26. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G, (2012) Identifying microRNA/mRNA dysregulations in ovarian cancer. BMC Res Notes 5: 164.
27. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, et al. (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14(9): 2690-2695.
28. Zhou X, Zhao F, Wang ZN, Song YX, Chang H, et al. (2012) Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep 27(2): 447-454.
29. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, et al. (2009) Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 114(2): 253-259.
30. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, et al. (2008) MicroRNA microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68(24): 10307-10314.
31. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, et al. (2009) MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 113(2): 249-255.
32. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih I, et al. (2008) MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 3(6): e2436.
33. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, et al. (2008) Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7: 35.
34. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, et al. (2006) microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103(24): 9136-9141.
35. Wang W, Peng B, Wang D, Ma X, Jiang D, et al. (2011) Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer 129(7): 1624-1634.
36. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, et al. (2011) Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections. Lancet Oncol 12(3): 273-285.
37. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, et al. (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: Correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102(3): 522-529.
38. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, et al. (2009) MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 219(2): 214-221.
39. Kobayashi D, Yamada M, Kamagata C, Kaneko R, Tsuji N, et al. (2002) Overexpression of early growth response-1 as a metastasis-regulatory factor in gastric cancer. Anticancer Res 22(6C): 3963-3970.
40. Unoki M, Nakamura Y, (2003) EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK. Oncogene 22(14): 2172-2185.
41. Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, et al. (2008) C-fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99(8): 1269-1275.
42. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T, (2004) Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem 279(10): 8567-8576.
43. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, et al. (2006) Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 66(17): 8404-8412.
44. Do TV, Kubba LA, Du H, Sturgis CD, Woodruff TK, (2008) Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 6(5): 695-705.
45. Inan S, Vatansever S, Celik-Ozenci C, Sanci M, Dicle N, et al. (2006) Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. Histol Histopathol 21(10): 1055-1064.
46. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, et al. (2007) Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 13(19): 5745-5755.
47. Wisman GB, Hollema H, Helder MN, Knol AJ, Van der Meer GT, et al. (2003) Telomerase in relation to expression of p53, c-myc and estrogen receptor in ovarian tumours. Int J Oncol 23(5): 1451-1459.
48. Chen CZ, (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353(17): 1768-1771.
49. Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, et al. (2008) Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 99(12): 2365-2372.
50. Li AJ, Baldwin RL, Karlan BY, (2003) Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 189(1): 22-27.
51. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, et al. (2009) Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma. Cancer Causes Control 20(1): 47-55.
52. Heckman CA, Duan H, Garcia PB, Boxer LM, (2006) Oct transcription factors mediate t(14;18) lymphoma cell survival by directly regulating bcl-2 expression. Oncogene 25(6): 888-889.
53. Xu D, Dwyer J, Li H, Duan W, Liu JP, (2008) Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-myc. J Biol Chem 283(35): 23567-23580.
54. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, et al. (2008) Ets-2 and p160 proteins collaborate to regulate c-myc in endocrine resistant breast cancer. Oncogene 27(21): 3021-3031.
55. Lourenco D, Brauner R, Lin L, De Perdigo A, Weryha G, et al. (2009) Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med 360(12): 1200-1210.
56. Dodson H (2011) Women with variants in "CLOCK" gene have higher risk of breast cancer. Yale Office of Public Affairs and Communications. Available: http://opac.yale.edu/news/article.aspx?id=7261. Accessed 24 January 2012.
57. Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, et al. (2010) CLOCK in breast tumorigenesis: Genetic, epigenetic, and transcriptional profiling analyses. Cancer Res 70(4): 1459-1468.
58. Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, et al. (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18(4): 769-774.
59. Ohuchida K, Mizumoto K, Lin C, Yamaguchi H, Ohtsuka T, et al. (2012) MicroRNA-10a is overexpressed in human pancreatic cancer and involved in its invasiveness partially via suppression of the HOXA1 gene. Ann Surg Oncol 19(7): 2394-2402.
60. Filippova GN, Qi CF, Ulmer JE, Moore JM, Ward MD, et al. (2002) Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. Cancer Res 62(1): 48-52.
61. Docquier F, Farrar D, D'Arcy V, Chernukhin I, Robinson AF, et al. (2005) Heightened expression of CTCF in breast cancer cells is associated with resistance to apoptosis. Cancer Res 65(12): 5112-5122.
62. Hiranuma C, Kawakami K, Oyama K, Ota N, Omura K, et al. (2004) Hypermethylation of the MYOD1 gene is a novel prognostic factor in patients with colorectal cancer. Int J Mol Med 13(3): 413-417.
63. Muller HM, Fiegl H, Widschwendter A, Widschwendter M, (2004) Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci 1022: 44-49.
64. Azuma T, Seki N, Yoshikawa T, Saito T, Masuho Y, et al. (2000) cDNA cloning, tissue expression, and chromosome mapping of human homolog of SOX18. J Hum Genet 45(3): 192-195.
65. Young N, Hahn CN, Poh A, Dong C, Wilhelm D, et al. (2006) Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization, and endothelial development. J Natl Cancer Inst 98(15): 1060-1067.
66. Johnson SA, Dubeau L, Kawalek M, Dervan A, Schonthal AH, et al. (2003) Increased expression of TATA-binding protein, the central transcription factor, can contribute to oncogenesis. Mol Cell Biol 23(9): 3043-3051.
67. Chen X, Thiaville MM, Chen L, Stoeck A, Xuan J,et al. Defining NOTCH3 target genes in ovarian cancer. Cancer Res 72(9): 2294-2303.
68. Zoref-Shani E, Lavie R, Bromberg Y, Beery E, Sidi Y, et al. (1994) Effects of differentiation-inducing agents on purine nucleotide metabolism in an ovarian cancer cell line. J Cancer Res Clin Oncol 120(12): 717-722.
69. Gao Z, Xu X, McClane B, Zeng Q, Litkouhi B, et al. (2011) C terminus of clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to taxol and carboplatin. Clin Cancer Res 17(5): 1065-1074.
70. Drakaki A, Iliopoulos D, (2009) MicroRNA gene networks in oncogenesis. Curr Genomics 10(1): 35-41.
71. Wu M, Chan C, (2011) Learning transcriptional regulation on a genome scale: A theoretical analysis based on gene expression data. Brief Bioinform 13(2): 150-161.
72. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67(18): 8699-8707.
73. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, et al. (2008) Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 105(19): 7004-7009.
74. Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, et al. (2009) Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol 114(2): 253-259.
75. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, et al. (2009) Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 4(4): e5311.
76. Unoki M, Nakamura Y, (2001) Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20(33): 4457-4465.
77. Mayr D, Hirschmann A, Marlow S, Horvath C, Diebold J, (2008) Analysis of selected oncogenes (AKT1, FOS, BCL2L2, TGFbeta) on chromosome 14 in granulosa cell tumors (GCTs): A comprehensive study on 30 GCTs combining comparative genomic hybridization (CGH) and fluorescence-in situ-hybridization (FISH). Pathol Res Pract 204(11): 823-830.
78. Chen CH, Shen J, Lee WJ, Chow SN, (2005) Overexpression of cyclin D1 and c-myc gene products in human primary epithelial ovarian cancer. Int J Gynecol Cancer 15(5): 878-883.